FXR expression in rats of hilar cholangiocarcinoma
The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimenta...
Saved in:
Published in | Scientific reports Vol. 12; no. 1; pp. 8741 - 7 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
24.05.2022
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma. |
---|---|
AbstractList | The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma. The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma. The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma. Abstract The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma. |
ArticleNumber | 8741 |
Author | Wang, Jie-ping Zhang, Meng-yu Luo, Ming |
Author_xml | – sequence: 1 givenname: Meng-yu surname: Zhang fullname: Zhang, Meng-yu organization: Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University – sequence: 2 givenname: Ming surname: Luo fullname: Luo, Ming organization: Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University – sequence: 3 givenname: Jie-ping surname: Wang fullname: Wang, Jie-ping email: 3529901542@qq.com organization: Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35610302$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kkFvFSEUhYmpsbX2D7gwk7hxMwoXmIGNiWmsNmliYjRxRxjm8h4v8-AJ86z-e2mn1baLsoHAOV9OLuc5OYgpIiEvGX3LKFfvimBSq5YCtAyUpO3lE3IEVMgWOMDBnfMhOSllQ-uSoAXTz8ghl12FUDgicPbja4O_dxlLCSk2ITbZzqVJvlmHyebGrdNk4yokZ7MLMW3tC_LU26ngyc1-TL6fffx2-rm9-PLp_PTDReukoHPrRia591r2bATnpVd8pOiE4lZIFF71ziJqD0wOg9WoLWcDYxQQBEXF-DE5X7hjshuzy2Fr8x-TbDDXFymvjM1zcBOajkre9dyxQY_CUrCDQtd7SQcArTWvrPcLa7cftjg6jHO20z3o_ZcY1maVfhnNOJW0q4A3N4Ccfu6xzGYbisOpzgbTvhjoOi0psF5W6esH0k3a51hHdaVSslOc06p6dTfRvyi3X1MFahG4nErJ6I0Ls53rJ9WAYTKMmqsimKUIphbBXBfBXFYrPLDe0h818cVUqjiuMP-P_YjrL_LTxGY |
CitedBy_id | crossref_primary_10_4110_in_2023_23_e6 crossref_primary_10_1002_iid3_727 |
Cites_doi | 10.1093/toxsci/kfz088 10.1016/j.lpm.2018.06.012 10.1245/s10434-021-11109-4 10.1002/jso.25722 10.3389/fphar.2019.00522 10.5009/gnl15568 10.1007/s10822-017-0021-x 10.1016/j.ejso.2017.04.001 10.1016/j.jhep.2018.06.022 10.1080/13543776.2018.1527906 10.12998/wjcc.v8.i1.68 10.1248/bpb.b18-00028 10.1053/j.gastro.2020.07.036 10.1172/JCI88893 10.1016/j.jpha.2019.04.004 10.1016/j.bbrc.2020.04.075 10.1097/MD.0000000000012025 10.1039/c9mt00274j 10.1007/164_2019_232 10.1159/000491715 10.1016/j.bbalip.2020.158733 10.1016/j.bbadis.2017.08.016 10.1371/journal.pone.0210077 10.1124/dmd.113.054304 10.1016/j.soc.2019.06.003 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.1038/s41598-022-12850-w |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 7 |
ExternalDocumentID | oai_doaj_org_article_6053673c1b9d4a02ab8ec7f50b229993 PMC9130506 35610302 10_1038_s41598_022_12850_w |
Genre | Journal Article |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c540t-cd153ff9571d2cf5f83d0ec483a45e4f87caee9f215bba9e9a31b1102e240e813 |
IEDL.DBID | M48 |
ISSN | 2045-2322 |
IngestDate | Wed Aug 27 01:31:40 EDT 2025 Thu Aug 21 18:21:43 EDT 2025 Fri Jul 11 06:26:36 EDT 2025 Wed Aug 13 08:19:50 EDT 2025 Wed Feb 19 02:26:09 EST 2025 Tue Jul 01 04:16:31 EDT 2025 Thu Apr 24 23:12:00 EDT 2025 Fri Feb 21 02:40:22 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-cd153ff9571d2cf5f83d0ec483a45e4f87caee9f215bba9e9a31b1102e240e813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-12850-w |
PMID | 35610302 |
PQID | 2668568330 |
PQPubID | 2041939 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6053673c1b9d4a02ab8ec7f50b229993 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9130506 proquest_miscellaneous_2669502175 proquest_journals_2668568330 pubmed_primary_35610302 crossref_citationtrail_10_1038_s41598_022_12850_w crossref_primary_10_1038_s41598_022_12850_w springer_journals_10_1038_s41598_022_12850_w |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-05-24 |
PublicationDateYYYYMMDD | 2022-05-24 |
PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2022 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Xiong (CR20) 2019; 10 Di Matteo (CR22) 2019; 14 Shinohara, Fujimori (CR26) 2020; 527 Lv (CR23) 2018; 48 Wang (CR8) 2018; 97 Gao (CR9) 2021; 16 Anderson, Doyle (CR2) 2019; 28 Gege, Hambruch, Hambruch, Kinzel, Kremoser (CR19) 2019; 256 Yang, Takeuchi, Tsuneyama, Tsuyoshi, Shingo (CR17) 2019; 170 Blechacz (CR1) 2017; 11 Celotti (CR7) 2017; 43 Jain, Grandits, Richter, Ecker (CR27) 2017; 31 Lu (CR10) 2019; 120 Preidis, Kim, Moore (CR5) 2017; 127 Ramos Pittol (CR6) 2020; 159 Köck (CR16) 2014; 42 Carino (CR25) 2020; 185 Zheng, Wang, Song, Ye, Xiang (CR14) 2019; 9 Barberis, Rossi, Filauro (CR13) 2019; 84 Takahashi, Ogra (CR15) 2020; 12 Yang (CR11) 2020; 8 Staub (CR12) 2020; 33 Erice (CR21) 2018; 1864 Toumi (CR29) 2018; 47 Wang, He, Wang, Xu, Hao (CR18) 2018; 28 Ploton (CR24) 2018; 69 Camerlo, Seux, Fara (CR3) 2022; 29 Dar (CR28) 2019; 29 Qu (CR4) 2018; 41 S Shinohara (12850_CR26) 2020; 527 A Barberis (12850_CR13) 2019; 84 XL Xiong (12850_CR20) 2019; 10 S Di Matteo (12850_CR22) 2019; 14 A Carino (12850_CR25) 2020; 185 FL Gao (12850_CR9) 2021; 16 GA Preidis (12850_CR5) 2017; 127 C Gege (12850_CR19) 2019; 256 Y Wang (12850_CR8) 2018; 97 XJ Yang (12850_CR11) 2020; 8 K Takahashi (12850_CR15) 2020; 12 S Jain (12850_CR27) 2017; 31 N Toumi (12850_CR29) 2018; 47 F Yang (12850_CR17) 2019; 170 H Wang (12850_CR18) 2018; 28 FS Dar (12850_CR28) 2019; 29 O Erice (12850_CR21) 2018; 1864 K Köck (12850_CR16) 2014; 42 JM Ramos Pittol (12850_CR6) 2020; 159 B Anderson (12850_CR2) 2019; 28 M Ploton (12850_CR24) 2018; 69 A Celotti (12850_CR7) 2017; 43 B Blechacz (12850_CR1) 2017; 11 J Lu (12850_CR10) 2019; 120 X Qu (12850_CR4) 2018; 41 B Lv (12850_CR23) 2018; 48 A Camerlo (12850_CR3) 2022; 29 J Staub (12850_CR12) 2020; 33 B Zheng (12850_CR14) 2019; 9 |
References_xml | – volume: 170 start-page: 95 year: 2019 end-page: 108 ident: CR17 article-title: Experimental evidence of liver injury by NTCP-inhibiting drugs with a bile salt supplementation in rats publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kfz088 – volume: 47 start-page: 950 year: 2018 end-page: 960 ident: CR29 article-title: Role of magnetic resonance imaging in preoperative assessement of hilar cholangiocarcinoma publication-title: Presse Med. doi: 10.1016/j.lpm.2018.06.012 – volume: 29 start-page: 2407 year: 2022 ident: CR3 article-title: Robotic left hepatectomy extended to caudate lobe and common biliary duct for hilar cholangiocarcinoma publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-021-11109-4 – volume: 120 start-page: 1341 year: 2019 end-page: 1349 ident: CR10 article-title: Prognostic significance of mucinous component in hilar cholangiocarcinoma after curative-intent resection publication-title: J. Surg. Oncol. doi: 10.1002/jso.25722 – volume: 10 start-page: 522 year: 2019 ident: CR20 article-title: Emodin rescues intrahepatic cholestasis via stimulating FXR/NTCP pathway in promoting the canalicular export of accumulated bile publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.00522 – volume: 11 start-page: 13 year: 2017 end-page: 26 ident: CR1 article-title: Cholangiocarcinoma: Current knowledge and new developments publication-title: Gut Liver doi: 10.5009/gnl15568 – volume: 31 start-page: 507 year: 2017 end-page: 521 ident: CR27 article-title: Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human NTCP publication-title: J. Comput. Aided Mol. Des. doi: 10.1007/s10822-017-0021-x – volume: 29 start-page: 874 year: 2019 end-page: 877 ident: CR28 article-title: Outcomes after surgical resection of hilar cholangiocarcinoma publication-title: J. Coll. Phys. Surg. Pak. – volume: 43 start-page: 1628 year: 2017 end-page: 1635 ident: CR7 article-title: Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis publication-title: Eur. J. Surg. Oncol. doi: 10.1016/j.ejso.2017.04.001 – volume: 69 start-page: 1099 year: 2018 end-page: 1109 ident: CR24 article-title: The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis publication-title: J. Hepatol. doi: 10.1016/j.jhep.2018.06.022 – volume: 28 start-page: 765 year: 2018 end-page: 782 ident: CR18 article-title: FXR modulators for enterohepatic and metabolic diseases publication-title: Expert Opin. Ther. Pat. doi: 10.1080/13543776.2018.1527906 – volume: 8 start-page: 68 year: 2020 end-page: 75 ident: CR11 article-title: Application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma publication-title: World J. Clin. Cases doi: 10.12998/wjcc.v8.i1.68 – volume: 41 start-page: 1211 year: 2018 end-page: 1218 ident: CR4 article-title: Dysregulation of NTCP and MRP2 May play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 cells publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.b18-00028 – volume: 159 start-page: 1853 year: 2020 end-page: 1865 ident: CR6 article-title: FXR isoforms control different metabolic functions in liver cells via binding to specific DNA Motifs publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.07.036 – volume: 33 start-page: 202 year: 2020 end-page: 209 ident: CR12 article-title: Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: A multicenter international study publication-title: Ann. Gastroenterol. – volume: 127 start-page: 1193 year: 2017 end-page: 1201 ident: CR5 article-title: Nutrient-sensing nuclear receptors PPARalpha and FXR control liver energy balance publication-title: J. Clin. Invest. doi: 10.1172/JCI88893 – volume: 9 start-page: 367 year: 2019 end-page: 372 ident: CR14 article-title: Pharmacokinetics and enterohepatic circulation of jervine, an antitumor steroidal alkaloid from Veratrum nigrum in rats publication-title: J. Pharm. Anal. doi: 10.1016/j.jpha.2019.04.004 – volume: 527 start-page: 49 year: 2020 end-page: 55 ident: CR26 article-title: Promotion of lipogenesis by PPARgamma-activated FXR expression in adipocytes publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2020.04.075 – volume: 97 start-page: e12025 year: 2018 ident: CR8 article-title: Effect of preoperative cholangitis on prognosis of patients with hilar cholangiocarcinoma: A systematic review and meta-analysis publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000012025 – volume: 12 start-page: 241 year: 2020 end-page: 248 ident: CR15 article-title: Identification of the biliary selenium metabolite and the biological significance of selenium enterohepatic circulation publication-title: Metallomics doi: 10.1039/c9mt00274j – volume: 16 start-page: 678 year: 2021 end-page: 685 ident: CR9 article-title: Insertion of I-125 seed-loaded stent for inoperable hilar cholangiocarcinoma publication-title: Wideochir Inne Tech. Maloinwazyjne – volume: 256 start-page: 167 year: 2019 end-page: 205 ident: CR19 article-title: Nonsteroidal FXR ligands: Current status and clinical applications publication-title: Handb. Exp. Pharmacol. doi: 10.1007/164_2019_232 – volume: 48 start-page: 158 year: 2018 end-page: 172 ident: CR23 article-title: FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting IL-6-induced epithelial-mesenchymal transition publication-title: Cell Physiol. Biochem. doi: 10.1159/000491715 – volume: 185 start-page: 158733 year: 2020 ident: CR25 article-title: Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis publication-title: Biochim. Biophys. Acta Mol. Cell Biol. Lipids. doi: 10.1016/j.bbalip.2020.158733 – volume: 1864 start-page: 1335 year: 2018 end-page: 1344 ident: CR21 article-title: Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression publication-title: Biochim. Biophys. Acta Mol. Basis Dis. doi: 10.1016/j.bbadis.2017.08.016 – volume: 14 year: 2019 ident: CR22 article-title: The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma publication-title: PLoS ONE doi: 10.1371/journal.pone.0210077 – volume: 42 start-page: 665 year: 2014 end-page: 674 ident: CR16 article-title: Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4 publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.113.054304 – volume: 28 start-page: 601 year: 2019 end-page: 617 ident: CR2 article-title: Surgical considerations of hilar cholangiocarcinoma publication-title: Surg. Oncol. Clin. N. Am. doi: 10.1016/j.soc.2019.06.003 – volume: 84 start-page: 245 year: 2019 end-page: 247 ident: CR13 article-title: Cholangitis mimicking hilar cholangiocarcinoma publication-title: Rev. Gastroenterol. Mex. – volume: 84 start-page: 245 year: 2019 ident: 12850_CR13 publication-title: Rev. Gastroenterol. Mex. – volume: 28 start-page: 601 year: 2019 ident: 12850_CR2 publication-title: Surg. Oncol. Clin. N. Am. doi: 10.1016/j.soc.2019.06.003 – volume: 47 start-page: 950 year: 2018 ident: 12850_CR29 publication-title: Presse Med. doi: 10.1016/j.lpm.2018.06.012 – volume: 170 start-page: 95 year: 2019 ident: 12850_CR17 publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kfz088 – volume: 185 start-page: 158733 year: 2020 ident: 12850_CR25 publication-title: Biochim. Biophys. Acta Mol. Cell Biol. Lipids. doi: 10.1016/j.bbalip.2020.158733 – volume: 97 start-page: e12025 year: 2018 ident: 12850_CR8 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000012025 – volume: 14 year: 2019 ident: 12850_CR22 publication-title: PLoS ONE doi: 10.1371/journal.pone.0210077 – volume: 42 start-page: 665 year: 2014 ident: 12850_CR16 publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.113.054304 – volume: 11 start-page: 13 year: 2017 ident: 12850_CR1 publication-title: Gut Liver doi: 10.5009/gnl15568 – volume: 29 start-page: 2407 year: 2022 ident: 12850_CR3 publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-021-11109-4 – volume: 31 start-page: 507 year: 2017 ident: 12850_CR27 publication-title: J. Comput. Aided Mol. Des. doi: 10.1007/s10822-017-0021-x – volume: 127 start-page: 1193 year: 2017 ident: 12850_CR5 publication-title: J. Clin. Invest. doi: 10.1172/JCI88893 – volume: 16 start-page: 678 year: 2021 ident: 12850_CR9 publication-title: Wideochir Inne Tech. Maloinwazyjne – volume: 159 start-page: 1853 year: 2020 ident: 12850_CR6 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.07.036 – volume: 1864 start-page: 1335 year: 2018 ident: 12850_CR21 publication-title: Biochim. Biophys. Acta Mol. Basis Dis. doi: 10.1016/j.bbadis.2017.08.016 – volume: 10 start-page: 522 year: 2019 ident: 12850_CR20 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.00522 – volume: 12 start-page: 241 year: 2020 ident: 12850_CR15 publication-title: Metallomics doi: 10.1039/c9mt00274j – volume: 69 start-page: 1099 year: 2018 ident: 12850_CR24 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2018.06.022 – volume: 29 start-page: 874 year: 2019 ident: 12850_CR28 publication-title: J. Coll. Phys. Surg. Pak. – volume: 527 start-page: 49 year: 2020 ident: 12850_CR26 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2020.04.075 – volume: 33 start-page: 202 year: 2020 ident: 12850_CR12 publication-title: Ann. Gastroenterol. – volume: 256 start-page: 167 year: 2019 ident: 12850_CR19 publication-title: Handb. Exp. Pharmacol. doi: 10.1007/164_2019_232 – volume: 9 start-page: 367 year: 2019 ident: 12850_CR14 publication-title: J. Pharm. Anal. doi: 10.1016/j.jpha.2019.04.004 – volume: 48 start-page: 158 year: 2018 ident: 12850_CR23 publication-title: Cell Physiol. Biochem. doi: 10.1159/000491715 – volume: 28 start-page: 765 year: 2018 ident: 12850_CR18 publication-title: Expert Opin. Ther. Pat. doi: 10.1080/13543776.2018.1527906 – volume: 41 start-page: 1211 year: 2018 ident: 12850_CR4 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.b18-00028 – volume: 8 start-page: 68 year: 2020 ident: 12850_CR11 publication-title: World J. Clin. Cases doi: 10.12998/wjcc.v8.i1.68 – volume: 43 start-page: 1628 year: 2017 ident: 12850_CR7 publication-title: Eur. J. Surg. Oncol. doi: 10.1016/j.ejso.2017.04.001 – volume: 120 start-page: 1341 year: 2019 ident: 12850_CR10 publication-title: J. Surg. Oncol. doi: 10.1002/jso.25722 |
SSID | ssj0000529419 |
Score | 2.37462 |
Snippet | The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target... Abstract The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 8741 |
SubjectTerms | 692/699/67 692/699/67/70 Alanine Alanine transaminase Animal models Animals Aspartate transaminase Bile Duct Neoplasms - pathology Bile ducts Bile Ducts, Intrahepatic - pathology Cholangiocarcinoma Cholangiocarcinoma - pathology Drug delivery Drug development Gene therapy Glyceraldehyde-3-phosphate dehydrogenase Humanities and Social Sciences Immunohistochemistry Klatskin Tumor - genetics Klatskin Tumor - pathology Male mRNA multidisciplinary Physical activity Polymerase chain reaction Rats Rats, Wistar Rodents Science Science (multidisciplinary) Therapeutic targets Transaminase Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LihQxFL3IgOBGfFs6SgnutJhUXpUsVWwGQRfiQO9Cnk6BpmW6h9G_9yZV3U773FjLqhSEk5ucc0lyLsDTNNigZSJdUEp0XFra6Uh4FzRVmI6pEKrZ89t38viEv1mK5aVSX-VM2GQPPAF3hHKbyYH53unALaHWqeiHJIijuJLq6vOJnHcpmZpcvanmvZ5vyRCmjtbIVOU2GS21PJQg3cUeE1XD_t-pzF8PS_60Y1qJaHEDrs8Ksn0x9fwmXIn5Flydakp-uw10sXzfxq_z-dbcjrnFQV63q9SejpjGtjWbzR9HJLEzP-bVZ3sHThavP7w67ubCCJ1HgbXpfMB1KiUthj5Qn0RSLJDouWKWi8iTGryNUSekc-esjtqy3iHP04j8HVXP7sJBXuV4H1rMPkIgTDgkdu6tdPh4SZyTTlluUwP9FiTjZ9fwUrzik6m710yZCViDwJoKrLlo4Nnuny-TZ8ZfW78s2O9aFr_r-gKjwMxRYP4VBQ0cbkfOzJNwbVB7KCEVY6SBJ7vPOH3KnojNcXVe22hR8jLRwL1poHc9YUVbMkIbGPZCYK-r-1_yeFotujVKA0FkA8-3wfKjW3-G4sH_gOIhXKMlyonoKD-Eg83ZeXyEwmnjHtc58h25UBIE priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k1KQUHiBlYdPxL7hACxqpDggKi0N8vPNhIkZXer0n_P2PGmWh7NMXYkZ2bsbz6PPYPQq9gZr9pIsJdSYN4ailUgHHtFJdAx6X1O9vz5S3t0zD8txbJsuK3LscrtmpgXaj-6tEd-CEAiRSuBfr89-4lT1agUXS0lNG6iWyl1WbLqbtnNeywpisUbVe7KECYP14BX6U4ZTRU9pCD4YgePctr-f_mafx-Z_CNumuFocQ_dLX5k_W5S_H10IwwP0O2psuTlQ0QXy691-FVOuQ51P9Sg6nU9xvq0BzJbZ047nPQAZSvXD-MP8wgdLz5--3CES3kE7MDN2mDnYbWKUYmu8dRFESXzJDgumeEi8Cg7Z0JQEUDdWqOCMqyxgPY0AIoH2bDHaG8Yh_AU1cBBvCdMWIB37kxr4XEtsba10nATK9RshaRdyR2eSlh81zmGzaSeBKtBsDoLVl9U6PX8zdmUOePa3u-T7OeeKet1fjGuTnSZRBqoF2s75hqrPDeEGiuD66IglgKqKlahg63mdJmKa31lOBV6OTfDJEqRETOE8Tz3USKxM1GhJ5Oi55Gw5GEyQivU7ZjAzlB3W4b-NCfqVuAgCNJW6M3WWK6G9X9R7F__F8_QHZrslwhM-QHa26zOw3NwjDb2Rbb-3xlvCjw priority: 102 providerName: ProQuest – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9RADA_nHYIv4rfVUyr4psXpfLQzj6u4HAv6oB7sW5nPu8LZyu4ep_-9memHrJ6CfWwzEJLM_JImkwC8DLV2qgqkcFKKgleaFsoTXjhFJYZj0rnU7PnDx-rklK_WYn0AdLoLk4r2U0vLdExP1WFvtgg08TIYjaM4pCDF1Q04iq3a0baPFovV59X8ZyXmrnipxhsyhMlrFu-hUGrWf52H-Weh5G_Z0gRCyztwe_Qe88XA71048N09uDnMk_xxH-hy_Sn338fa1i5vuxwVvM37kJ-3GMLmKZLtzloEsI1tu_6rfgCny_df3p0U41CEwqJztSuswzMqBCXq0lEbRJDMEW-5ZJoLz4OsrfZeBYRyY7TySrPSIMZTj9jtZckewmHXd_4x5Bh5OEeYMAjq3OrK4GMrYkxlpOY6ZFBOQmrs2DE8Dq64aFLmmslmEGyDgm2SYJurDF7Na74N_TL-Sf02yn6mjL2u04t-c9aMum8w4GJVzWxplOOaUG2kt3UQxFDEUsUyOJ4014wbcNug3yFFJRkjGbyYP-PWifkQ3fn-MtEoEWMykcGjQdEzJyz6lYzQDOo9E9hjdf9L156n9twK3QJBqgxeT8byi62_i-LJ_5E_hVs02jMRBeXHcLjbXPpn6B7tzPNxP_wEqfMJ2Q priority: 102 providerName: Springer Nature |
Title | FXR expression in rats of hilar cholangiocarcinoma |
URI | https://link.springer.com/article/10.1038/s41598-022-12850-w https://www.ncbi.nlm.nih.gov/pubmed/35610302 https://www.proquest.com/docview/2668568330 https://www.proquest.com/docview/2669502175 https://pubmed.ncbi.nlm.nih.gov/PMC9130506 https://doaj.org/article/6053673c1b9d4a02ab8ec7f50b229993 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD70wmAvY_d664IHe9u8ybrY0sMYaWgogZbRLZA3I8lSG-icLUlp--93JDsZ2bIxvxgk2YhPR_6-Y0nnALzxpa5V4UlWSykyXmiaKUd4Visq0R2TdR2DPZ-eFSdjPpqIyQ6s0h11AC62unYhn9R4fvX-9sfdJ5zwH9sj4_LDAkkoHBSjIU2HFCS72YV9ZKYyZDQ47eR-G-ubKh5zfYQg7BmKCdqdo9n-mg2uiiH9t-nQP7dT_ramGqlq-BAedBoz7bdG8Qh2XPMY7rVZJ--eAB1OzlN32-2AbdJpk6IZLNKZTy-niEYaQWkupkhzczttZt_0UxgPj78OTrIudUJmUYItM1vjl8x7Jcq8ptYLL1lNnOWSaS4c97K02jnlkfCN0copzXKDSoA6ZHgnc_YM9ppZ4w4gRf-krgkTBqmfW10YvGxBjCmM1Fz7BPIVSJXt4oqH9BZXVVzfZrJqga0Q2CoCW90k8Hb9zPc2qsY_Wx8F7NctQ0TsWDCbX1TdBKvQLWNFyWxuVM01odpIZ0sviKHIuIolcLgauWplZRWqEykKyRhJ4PW6GidYWDXRjZtdxzZKBM9NJPC8Heh1T1hQn4zQBMoNE9jo6mZNM72MQbwVigdBigTerYzlV7f-DsWL_-jmS7hPgxETtHB-CHvL-bV7hcppaXqwW07KHuz3-6MvI7wfHZ99PsfSQTHoxb8RvThhfgKxVBdZ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4k2gQJDgBFEdPxL7gBCvVUsfB9RKezN-titBUna3Wvqn-I2MnWSr5dFbc0ycyBnP-JvPY88g9CLU2skq4MIJwQtWaVJIj1nhJBFAx4RzKdnz3n61dcg-j_l4Df0azsLEbZXDnJgmatfauEa-CUAieCWAfr89-VHEqlExujqU0OjUYsefLYCyzd5sf4TxfUnI6NPBh62irypQWPBO5oV1YOQhSF6XjtjAg6AOe8sE1Yx7FkRttfcyABYao6WXmpYGQJJ4AD8vSgrfvYKuAvDiSPbqcb1c04lRM1bK_mwOpmJzBvgYz7CRWEFEcFwsVvAvlQn4l2_79xbNP-K0Cf5Gt9DN3m_N33WKdhut-eYOutZVsjy7i8ho_CX3P_tdtU0-aXJQrVnehvx4AuQ5Txy6OZoAdE7tpGm_63vo8FIEdx-tN23jH6IcOI9zmHID7gSzujJw2QobUxmhmQ4ZKgchKdvnKo8lM76pFDOnQnWCVSBYlQSrFhl6tXznpMvUcWHr91H2y5Yxy3a60U6PVG-0CqgerWpqSyMd05hoI7ytA8eGAIpLmqGNYeRUb_ozda6oGXq-fAxGGyMxuvHtaWojeWSDPEMPuoFe9oRGj5ZikqF6RQVWurr6pJkcp8TgEhwSjqsMvR6U5bxb_xfFo4v_4hm6vnWwt6t2t_d3HqMbJOoy5gVhG2h9Pj31T8Apm5unyRJy9PWyTe83pjZH6Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrUBcEG8CBYIEJ4jWsePEPiBEaVcthVVVUam34Ge7EiRld6ulf41fxziPrZZHb80xcSJnPONvPo89A_DSF8rK3JPECsGTLFc0kY5kiZVUIB0T1jbJnj-P853D7OMRP1qDX_1ZmLCtsp8Tm4na1iaskQ8RSATPBdLvoe-2Rexvjd6d_khCBakQae3LabQqsufOF0jfZm93t3CsX1E62v7yYSfpKgwkBj2VeWIsGrz3kheppcZzL5glzmSCqYy7zIvCKOekR1zUWkknFUs1AiZ1CIROpAy_ew3Wi8CKBrC-uT3eP1iu8IQYWpbK7qQOYWI4Q7QMJ9poqCciOEkWK2jYFA34l6f794bNP6K2DRiObsOtzouN37dqdwfWXHUXrrd1Lc_vAR0dHcTuZ7fHtoonVYyKNotrH59MkErHDaOujicIpFMzqerv6j4cXonoHsCgqiv3CGJkQNYSxjU6F5lRucbL5ETrXAuVKR9B2gupNF3m8lBA41vZRNCZKFvBlijYshFsuYjg9fKd0zZvx6WtN4Psly1Dzu3mRj09LjsTLpH4sbxgJtXSZopQpYUzhedEU8R0ySLY6Eeu7CaCWXmhthG8WD5GEw5xGVW5-qxpI3nghjyCh-1AL3vCgn_LCI2gWFGBla6uPqkmJ02acInuCSd5BG96Zbno1v9F8fjyv3gON9Dsyk-7470ncJMGVSY8odkGDObTM_cUPbS5ftaZQgxfr9r6fgOUPk2E |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FXR+expression+in+rats+of+hilar+cholangiocarcinoma&rft.jtitle=Scientific+reports&rft.au=Zhang%2C+Meng-Yu&rft.au=Luo%2C+Ming&rft.au=Wang%2C+Jie-Ping&rft.date=2022-05-24&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=8741&rft_id=info:doi/10.1038%2Fs41598-022-12850-w&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |